The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication
- 15 April 2015
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 17 (5) , 1-13
Abstract
Juvenile idiopathic arthritis (JIA) is a poorly understood, heterogeneous, incurable, inflammatory syndrome. Long-term outcomes are uncertain, and this painful condition can result in lifelong disability. JIA is associated with considerable financial and humanistic burden for those affected and the healthcare system. Early diagnosis and effective treatment are indicated to optimise outcomes. Modern treatment aims to achieve remission and preserve joint function by using disease-modifying antirheumatic drugs (DMARDs) early. DMARDs can be classified as conventional/traditional or biologic. Biologic medications may be more effective but cost approximately ten times more than traditional DMARDs. Decision-makers in healthcare are increasingly comparing the cost and consequences of alternative treatment strategies to guide resource allocation decisions. There have been few economic evaluations to date to guide medicines optimisation in JIA. This systematic review highlights the lack of existing evidence relating to the humanistic and economic burden of JIA in the era of biologic medication.Keywords
This publication has 53 references indexed in Scilit:
- The financial burden of juvenile idiopathic arthritis: a Nova Scotia experiencePediatric Rheumatology, 2013
- Health-related quality of life in girls and boys with juvenile idiopathic arthritis: self- and parental reports in a cross-sectional studyPediatric Rheumatology, 2012
- Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritisBMC Pediatrics, 2012
- Economic impact of juvenile idiopathic arthritis and familial Mediterranean feverRheumatology International, 2011
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresArthritis Care & Research, 2011
- Health-related quality of life changes of children and adolescents with chronic disease after participation in therapeutic recreation camping programHealth and Quality of Life Outcomes, 2011
- Productivity Loss Due to Presenteeism Among Patients with Arthritis: Estimates from 4 InstrumentsThe Journal of Rheumatology, 2010
- How Accurate are Self-Reports? Analysis of Self-Reported Health Care Utilization and Absence When Compared With Administrative DataJournal of Occupational and Environmental Medicine, 2009
- Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosisRheumatology, 2008
- Priority setting in health care: Lessons from the experiences of eight countriesInternational Journal for Equity in Health, 2008